Last reviewed · How we verify
APL-1202 treatment
APL-1202 treatment targets the PD-1/PD-L1 pathway to modulate the immune response.
APL-1202 treatment targets the PD-1/PD-L1 pathway to modulate the immune response. Used for Non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | APL-1202 treatment |
|---|---|
| Sponsor | Jiangsu Yahong Meditech Co., Ltd aka Asieris |
| Drug class | PD-1/PD-L1 inhibitor |
| Target | PD-1/PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
APL-1202 is an immunotherapy that works by blocking the PD-1/PD-L1 interaction, which is a key checkpoint in the immune system. This allows the immune system to recognize and attack cancer cells more effectively.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Rash
- Pyrexia
Key clinical trials
- A Study of APL-1501 Extended Release Capsules Compared to APL-1202 Immediate Release Tablets in Healthy Volunteers (PHASE1)
- A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers (PHASE1)
- Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients (PHASE3)
- A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer (PHASE1, PHASE2)
- A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients (PHASE3)
- A Phase I, Two-phase, Crossover Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APL-1501 ER Tablets (PHASE1)
- Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG Therapy (PHASE2)
- Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- APL-1202 treatment CI brief — competitive landscape report
- APL-1202 treatment updates RSS · CI watch RSS
- Jiangsu Yahong Meditech Co., Ltd aka Asieris portfolio CI